NCT02668692已完成3 期
Efficacy and Safety of LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis Vulgaris
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- LEO Pharma
- 入组人数
- 213
- 试验地点
- 1
- 主要终点
- Number of Subjects With 'Overall Improvement' for the Target Lesion on the Scalp
研究概览
简要总结
To compare the efficacy and safety of LEO 80185 gel with Dovobet® ointment in the treatment of psoriasis in Japanese subjects.
详细描述
A phase 3, national, multi-centre, 4-week, prospective, randomised, controlled, parallel-group, open trial of LEO 80185 gel versus Dovobet® ointment in Japanese subjects with psoriasis vulgaris.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Informed consent has been obtained.
- •Japanese subjects
- •Aged 20 years or above
- •Clinical diagnosis of psoriasis vulgaris amenable to topical treatment of less than or equal to 30% BSA
- •A target psoriasis lesion on the scalp and on the non-scalp area of the body, each lesion of a minimum size of 10 cm2 and scoring at least 2 (mild) for each of the clinical signs (redness, thickness and scaliness).
- •Females of childbearing potential must have a negative result for a urine pregnancy test at Day 1 (Visit 1) and must agree to use an adequate method of birth control.
- •Able to communicate with the (sub)investigator and understand and comply with the requirements of the trial.
排除标准
- •Systemic use of biological treatments with a potential effect on psoriasis vulgaris
- •Systemic treatments with all therapies other than biological treatments with a potential effect on psoriasis vulgaris
- •PUVA therapy, UVB therapy or UVA therapy
- •Topical treatment of psoriasis on the areas to be treated with trial medication
- •Topical treatment of psoriasis on the face, genitals or skin folds with vitamin D analogues, potent or very potent corticosteroids or immunosuppressants
- •Topical treatment of conditions other than psoriasis with vitamin D analogues, potent or very potent corticosteroids or immunosuppressants
- •Planned initiation of, or changes in, concomitant medication that may affect psoriasis vulgaris
- •Patients with any of the following disorders (a) or symptoms (b) present on the areas to be treated with trial medication: (a) viral (e.g., herpes or varicella) lesions of the skin, fungal, spirochetal or bacterial skin infections, parasitic infections, skin manifestations in relation to syphilis or tuberculosis, rosacea, acne vulgaris, atrophic skin, striae atrophicae, ichthyosis, acne rosacea, ulcers, burns, frostbite, wounds, animal skin disease (scabies, crabs, lice, etc.) or (b) fragility of skin veins.
- •Other inflammatory skin diseases that may confound the evaluation of psoriasis vulgaris.
- •Erythrodermic, exfoliative or pustular psoriasis
- •Planned excessive exposure of areas to be treated with trial medication to either natural or artificial sunlight
- •Known or suspected disorders of calcium metabolism associated with hypercalcaemia, or albumin-corrected serum calcium above the reference range
- •Known or suspected severe renal insufficiency, severe hepatic disorders or severe heart disease.
- •Known or suspected hypersensitivity to any components of the investigational products.
- •Clinical signs or symptoms of Cushing's disease or Addison's disease
- •Treatment with any non-marketed drug substance
- •Current participation in any other interventional clinical trial
- •Previously randomised in this trial
- •Females who are pregnant, wishing to become pregnant or are breast-feeding
研究组 & 干预措施
LEO 80185 gel
Experimental
干预措施: LEO 80185 gel (Drug)
Dovobet ® ointment
Active Comparator
干预措施: Dovobet ® ointment (Drug)
结局指标
主要结局
Number of Subjects With 'Overall Improvement' for the Target Lesion on the Scalp
时间窗: End of Week 4
'Overall improvement' for the target lesion on the scalp, defined as 'substantial resolution' of clinical signs and/or at least 'moderately improved' in the general change in the lesion. 'Substantial resolution' is defined as a clinical score for thickness and scaliness of 0 and a clinical score for redness of 1 or less in the severity of clinical signs of the lesion.
次要结局
- Number of Subjects With 'Overall Improvement' for the Target Lesion on the Non-scalp Area of the Body(End of Week 4)
- The Change in the Sum of the Scores (Total Sign Score) for the Severity of the 3 Clinical Signs:Thickness, Scaliness, Redness From Baseline to End of Week 4 (Visit 1-4) for Each Target Lesion.(From Baseline to end of Week 4 (Visit 1-4))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Dermatopharmacokinetic Trial of LEO 80185 GelPsoriasis VulgarisNCT02605057LEO Pharma32
已完成
3 期
LEO 90105 Ointment in Japanese Subjects With PsoriasisPsoriasisNCT01422434LEO Pharma676
已完成
2 期
LEO19123 Cream in the Treatment of Atopic DermatitisAtopic DermatitisNCT00392067LEO Pharma75
已完成
3 期
Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis VulgarisPsoriasis VulgarisNCT03806790LEO Pharma182
已完成
2 期
Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp PsoriasisScalp PsoriasisNCT01120223LEO Pharma78